Nearly 4 out of 5 that progress to biopsy are benign. Nearly 4 times that are called for additional evaluation. The false positives are quite high compared to other imaging. It is designed that way, to decrease the chances of a false negative.
The false negative rate is also quite high. It will miss about 1 in 5 women with cancer. The reality is mammography is just not all that powerful as a screening tool. That’s why the criteria for who gets screened and how often has been tailored to try and ensure the benefits outweigh the risks. Although it is an ongoing debate in the medical community to determine just exactly what those criteria should be.
Nearly 4 out of 5 that progress to biopsy are benign. Nearly 4 times that are called for additional evaluation. The false positives are quite high compared to other imaging. It is designed that way, to decrease the chances of a false negative.
The false negative rate is also quite high. It will miss about 1 in 5 women with cancer. The reality is mammography is just not all that powerful as a screening tool. That’s why the criteria for who gets screened and how often has been tailored to try and ensure the benefits outweigh the risks. Although it is an ongoing debate in the medical community to determine just exactly what those criteria should be.